Searched for
MOUNJARO CARDIOVASCULAR APPROVAL
Eli Lilly’s Mounjaro wins FDA approval for a major new cardiovascular benefitEli Lilly's Mounjaro received FDA approval for reducing heart attack and stroke risks. This new indication expands its use beyond diabetes ...- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- Lilly's weight-loss pill shows better blood sugar control in late-stage trialsEli Lilly's experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients across two lat...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could loseEli Lilly's experimental weight loss pill, orforglipron, demonstrated an average weight loss of 12% in a late-stage trial, falling short of...
- Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patientsEli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, reducing mortality a...
- Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underwayDriven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....
- Delhi HC seeks regulator's reply after PIL questions Ozempic, Mounjaro nodThe Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like Ozempic and Mounja...
- A big fat fight has just broken out in IndiaIndia's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gain...
- Novo Nordisk aims for heavy sales in India with WegovyThe achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...
- New study on Ozempic reveals shocking effects on eating habitsA new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating habits. The stud...
- Novo Nordisk readies to bring weight-loss drug Wegovy to IndiaDanish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform El...
- Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in IndiaDoctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resor...
- Eli Lilly in advanced clinical trials for its weight-loss pillEli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...
- Novo Nordisk India head eyes 2026 launch for obesity drug Wegovy, warns against copycatsNovo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure suff...
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...
Load More
